AIM ImmunoTech Inc
aimimmuno.comWhat Do They Do?
Develops Ampligen as a treatment for pancreatic cancer and other cancers, viral diseases and immune disorders, and Alferon N Injection for genital warts.
10-K for FY2025, filed Mar 27, 2026AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and…View ↗
AIM’s products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). The Company’s flagship product –Ampligen – is a…View ↗
Based on clinical success as to safety and efficacy in our pancreatic cancer Early Access Program and an ongoing Phase 2 trial, AIM has…View ↗
Regulation by governmental authorities in the U.S. and foreign countries is and will be a significant factor in the manufacture and…View ↗
How Do They Make Money?
AIM sells Ampligen through cost-recovery clinical treatment programs: under FDA-approved protocols, sales are tied to shipment; in the early-access program, they are tied to distribution and administration to patients.
10-K for FY2025, filed Mar 27, 2026
$88K
-
10-K for FY2025, filed Mar 27, 2026
$88K ↗
Who Are Their Customers?
Ampligen reaches patients through partners: Filaxis was contracted to commercialize it in Argentina, while myTomorrows serves as an early-access service provider and distributor in Europe and Turkey.
10-K for FY2025, filed Mar 27, 2026
Do Revenues Turn Into Profits?
No. It lost $14M in FY2025.
10-K for FY2025, filed Mar 27, 2026
How Are They Changing?
Shrinking. Revenue fell 35% in 4 years, from $135K in FY2021 to $88K in FY2025, about 10% a year.
Narrower development focus
The older report prioritized pancreatic cancer, chronic fatigue and post-COVID programs alongside antiviral research; the latest report says the company has chosen to focus its efforts on Ampligen for late-stage pancreatic cancer.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026We are prioritizing our activities in an order related to the stage of development, with those clinical activities such as pancreatic…View ↗
Based on clinical success as to safety and efficacy in our pancreatic cancer Early Access Program and an ongoing Phase 2 trial, AIM has…View ↗
Who Do They Compete With?
Competes with Pfizer, GlaxoSmithKline, Merck &, Novartis, AstraZeneca, Revolution Medicines, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma, and Genta
10-K for FY2025, filed Mar 27, 2026The major pharmaceutical competitors for Ampligen include Pfizer, GlaxoSmithKline, Merck & Co., Novartis and AstraZeneca. Biotech…View ↗
Loading...
